



FIRST MEDITERRANEAN CONFERENCE

on open issues and new waves in immunotherapy and targeted therapy
-to stay, to go away, to come back-

May 24th, 2024

Naples | Grand Hotel Santa Lucia
via Partenope 46

3PSOLUTION
A CENCORA Company

Under the auspices of:



SCIENTIFIC RATIONAL

Recent advances in cancer treatment have brought new waves of immunotherapy and targeted therapy. Key immunotherapy approaches include immune checkpoint inhibitors, CAR-T cell therapy and cancer vaccines, which are revolutionising treatment options and improving patient outcomes. Meanwhile, by targeting specific pathways essential for cancer growth, targeted therapies minimise damage to healthy cells, leading to more effective and less toxic treatments. Precision medicine techniques, such as genomic profiling, help identify suitable targets for these therapies, enabling personalised treatment strategies tailored to individual patients.

These innovative approaches represent significant advances in the fight against cancer, offering hope for improved survival rates and better quality of life. As research continues to unravel the complexities of cancer biology, the future of immunotherapy and targeted therapy holds great promise for changing the landscape of cancer care.

SCIENTIFIC PROGRAM

- 08.30 **Registration****
- 08.45 **Welcome address****
Margaret Ottaviano
- 09.00 **LECTIO MAGISTRALIS: The immunotherapy landscape beyond anti-CTLA4 and anti-PD (L)1**
Paolo A. Ascierto
- 09.20 **LECTIO MAGISTRALIS: The paradigm shifting from genomically driven to tissue agnostic approval in cancer therapy**
Umberto Malapelle
- SESSION 1: Overcoming immunotherapy resistance**
Discussants: Roberto Ferrara, Margaret Ottaviano
- 09.40 **Discussants and Speakers pills**
Roberto Ferrara, Margaret Ottaviano
- 09.45 **Non-oncogene addicted non small cell lung cancer**
Giuseppe Viscardi
- 10.00 **Melanoma and non melanoma skin cancers**
Luisa Piccin
- 10.15 **Triple negative breast cancer**
Giuseppe Buono
- 10.30 **Upper GI cancers**
Michele Ghidini
- 10.45 **Discussion about overcoming immunotherapy resistance**
G. Buono, R. Ferrara, M. Ghidini, M. Ottaviano, L. Piccin, G. Viscardi
- 10.55 **Coffee Break****

*** Not included in the CME accredited program*

SESSION 2: Targeted therapy resistance and innovation

Discussants: Margaret Ottaviano, Mario Rosanova

- 11.05 **Discussants and Speakers pills**
Margaret Ottaviano, Mario Rosanova
- 11.10 **Oncogene addicted non small cell lung cancer**
Carminia Della Corte
- 11.25 **Melanoma**
Vito Vanella
- 11.40 **CDK4/6 inhibitors resistance in breast cancer**
Martina Pagliuca
- 11.55 **Antibody-Drug Conjugates: Innovation in breast cancer**
Francesco Schettini
- 12.10 **Hepatocarcinoma and cholangiocarcinoma**
Margherita Muratore
- 12.25 **Discussion about targeted therapy resistance and innovation**
C. Della Corte, M. Muratore, M. Ottaviano, M. Pagliuca, M. Rosanova, F. Schettini, V. Vanella
- SESSION 3: The permanent open issues in rare cancers**
Discussants: Erica Pietroluongo, Salvatore Provenzano
- 12.35 **Discussants and Speakers pills**
Erica Pietroluongo, Salvatore Provenzano
- 12.40 **Antiangiogenesis and immunotherapy in thymic epithelial tumors**
Martina Imbimbo
- 12.55 **Immunotherapy in soft tissue sarcoma**
Alessandra Merlini

*** Not included in the CME accredited program*

- 13.10 **Novelties in neuroendocrine carcinoma**
Anna La Salvia
- 13.25 **Discussion about the permanent open issues in rare cancers**
M. Imbimbo, A. La Salvia, A. Merlini, E. Pietroluongo, S. Provenzano
- 13.35 **Lunch****
- SESSION 4: Combination vs sequential strategy: what's new and what's better**
Discussants: Vincenza Conteduca, Daniele Raggi
- 14.25 **Discussants and Speakers pills**
Vincenza Conteduca, Daniele Raggi
- 14.30 **Kidney cancer**
Laura Marandino
- 14.45 **Urothelial cancer**
Brigida Maiorano
- 15.00 **Melanoma and non melanoma skin cancers**
Maria Grazia Vitale
- 15.15 **Breast cancer**
Claudia von Arx
- 15.30 **Discussion about combination vs sequential strategy: what's new and what's better**
V. Conteduca, B. Maiorano, L. Marandino, D. Raggi, M.G. Vitale, C. von Arx
- SESSION 5: The sooner the better: neoadjuvant or adjuvant?**
Discussants: Claudia Cardone, Mario Giuliano
- 15.40 **Discussants and Speakers pills**
Claudia Cardone, Mario Giuliano
- 15.45 **Upper GI cancers**
Angelica Petrillo

*** Not included in the CME accredited program*

- 16.00 **Triple negative and HER2 positive breast cancers**
Vincenzo Di Lauro
- 16.15 **Colo-rectal cancers**
Debora Basile
- 16.30 **Endometrial and cervix cancer**
Valentina Tuninetti
- 16.45 **Discussion about the sooner the better: neoadjuvant or adjuvant?**
D. Basile, C. Cardone, V. Di Lauro, M. Giuliano, A. Petrillo, V. Tuninetti
- SESSION 6: Immunotherapy: failure or not failure?**
Discussants: Alessio Cortellini, Jole Ventriglia
- 16.55 **Discussants and Speakers pills**
Alessio Cortellini, Jole Ventriglia
- 17.00 **Metastatic castration resistance prostate cancer**
Pasquale Rescigno
- 17.15 **Pancreas adenocarcinoma**
Francesca Foschini
- 17.30 **Glioblastoma**
Marta Padovan
- 17.45 **Ovaric cancer**
Laura Attademo
- 18.00 **Discussion about immunotherapy: failure or not failure?**
L. Attademo, A. Cortellini, F. Foschini, M. Padovan, P. Rescigno, J. Ventriglia
- 18.10 **Conclusions**
Margaret Ottaviano

SCIENTIFIC DIRECTOR

Margaret Ottaviano

Dirigente Medico - UOC di Melanoma, Immunoterapia Oncologica e Terapie Innovative, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Napoli

FACULTY

Paolo A. Ascierto

Director of Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Napoli

Laura Attademo

Dirigente Medico - Ospedale del Mare, Napoli

Debora Basile

Medico Oncologo - UOC di Oncologia Medica, Ospedale San Giovanni di Dio, Crotone

Giuseppe Buono

Dirigente Medico - Dipartimento di Oncologia Senologica, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Napoli

Claudia Cardone

Dirigente Medico - SC Oncologia Clinica Sperimentale Addome, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Napoli

Vincenza Conteduca

Professore Associato e Dirigente Medico - UO di Oncologia Medica e Terapia Biomolecolare, Università di Foggia

Alessio Cortellini

Medico e Ricercatore Universitario - Fondazione Policlinico Universitario Campus Bio-Medico ed Università Campus Bio-Medico, Roma (IT) - Honorary Clinical Lecturer. Imperial College London, Londra (UK)

Carminia Maria Della Corte

Ricercatore - UOC Oncologia Medica ed Ematologia, Dipartimento di Medicina di Precisione, Università degli Studi della Campania "Luigi Vanvitelli", Napoli

Vincenzo Di Lauro

Dirigente Medico - SC Oncologia Clinica Sperimentale di Senologia, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Roberto Ferrara

Medico Oncologo e Ricercatore - Università Vita e Salute San Raffaele, Milano

Francesca Foschini

Dirigente Medico - SC Oncologia Clinica Sperimentale Addome, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Napoli

Michele Ghidini

Dirigente Medico - Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano

Mario Giuliano

Professore Associato e Dirigente Medico, Università Federico II, Napoli

Martina Imbimbo	Medical Oncologist - Medical Oncology and Drug Development Unit, Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland
Anna La Salvia	Researcher - National Center for Drug Research and Evaluation National Institute of Health (ISS), Rome
Brigida Anna Maiorano	Dirigente Medico - Dipartimento di Oncologia, Ospedale San Raffaele IRCCS, Milano
Umberto Malapelle	Professore Associato - Dipartimento di Sanità Pubblica, Università degli Studi di Napoli Federico II
Laura Marandino	Clinical Research Fellow - Royal Marsden NHS Foundation Trust, London, UK
Alessandra Merlini	Oncologo Medico - Dipartimento di Oncologia, Ospedale Universitario San Luigi Gonzaga, Orbassano (TO)
Margherita Muratore	Dirigente Medico - IRST - Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola, FC
Margaret Ottaviano	Dirigente Medico - UOC di Melanoma, Immunoterapia e Terapie Innovative, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Napoli
Marta Padovan	Dirigente Medico del gruppo tumori cerebrali IOV - Oncologia 1, Istituto Oncologico Veneto IOV - IRCCS Padova, Padova
Martina Pagliuca	Oncologo Medico e PhD Student - Gustave Roussy, Villejuif, Ile-de-France, Francia
Angelica Petrillo	Dirigente Medico - UOC Oncologia, Ospedale del Mare, Napoli
Luisa Piccin	Dirigente Medico - UOC Oncologia 2, IOV - Istituto Oncologico Veneto, Padova
Erica Pietrolungo	Oncologo Medico e PhD student - Dipartimento di Medicina Clinica e Chirurgia, Università Federico II, Napoli
Salvatore Provenzano	Dirigente Medico - Oncologia Medica 2 - Tumori Mesenchimali e Rari, Fondazione IRCCS - Istituto Nazionale Tumori, Milano
Daniele Raggi	Medical Oncologist - The Royal Marsden Hospital NHS Trust, London, UK
Pasquale Rescigno	Senior Lecturer, Head of the Interdisciplinary Group for Translational Research and Clinical Trial, GU cancers, Newcastle University - Newcastle, UK
Mario Rosanova	Ospedale del Mare (ASL Napoli 1 Centro), Napoli

Francesco Schettini

Dirigente Medico - Dipartimento di Oncologia Medica del Hospital Clínico de Barcelona e ricercatore post-doc nel gruppo di ricerca Translational Genomics and Targeted Therapies in Solid Tumors del IDIBAPS, Barcellona, Spagna

Valentina Tuninetti

Dirigente Medico - Dipartimento di Oncologia, Università degli Studi di Torino, SCU Oncologia, AO Ordine Mauriziano, Ospedale Umberto I, Torino

Vito Vanella

Dirigente Medico - UOC Oncologia Melanoma, Immunoterapie Oncologiche e Terapie Innovative, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Napoli

Jole Ventriglia

Dirigente Medico - SC Oncologia Clinica Sperimentale Uro-Ginecologica, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Napoli

Giuseppe Viscardi

Dirigente Medico - UOC Oncologia Ospedale Monaldi - AORN Ospedali dei Colli, Napoli

Maria Grazia Vitale

Dirigente Medico - SC Oncologia Clinica Sperimentale Melanoma, Immunoterapia e Terapie Innovative, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Napoli

Claudia Von Arx

Dirigente Medico - SC Oncologia Clinica Sperimentale di Senologia, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Napoli

CONTINUING MEDICAL EDUCATION

3P Solution has been accredited by the Ministry of Health as a CME Standard Provider (code 327, authorized on October 15th, 2012).

3P Solution owns the responsibility for the content, quality and ethical correctness of this CME activity.

The number of attendees can not exceed the number of accredited participants. If the number of participants is exceeded, attendees will be admitted to the scientific sessions on the basis of registration order.

The event has been accredited (ID CME 327-414819) with **8 CME credits** with a **formative objective** "Epidemiology - prevention and health promotion - diagnostics - toxicology with acquisition of technical-professional knowledge (formative field: formative technical-professional objectives) for **80 participants** of the following professions: **Biologist; Pharmacist:** other sector pharmacist, NHS public pharmacist, community pharmacist; **Nurse; Physician:** Allergology and Clinical Immunology, Pathological Anatomy, Clinical Biochemistry, General Surgery, Plastic and Reconstructive Surgery, Palliative Care, Dermatology and Venereology, Hematology, Endocrinology, Epidemiology, Pharmacology and Clinical Toxicology, Gastroenterology, Medical Genetics, Geriatrics, Obstetrics and Gynecology, Laboratory of Medical Genetics, Respiratory Diseases, Internal Medicine, Nuclear Medicine, Nephrology, Oncology, Clinical Pathology (Laboratory of Chemical-Clinical Analysis and Microbiology), Radio diagnostics, Radiotherapy, Urology.

MYECM

Age.na.s activated MyEcm service (personalized page available to any health professional), which enables you to:

1. Consult the CME events offer;
2. Refer to the summary of events attended and earned credits;
3. Provide an assessment of courses organized by the Provider.

To access online services please log on to <http://ape.agenas.it/professionisti/myecm>.

If this meeting fulfilled your expectations, please click  and give your assessment.

HOW TO REGISTER

Log on to the DEEP ECM platform: <https://ecm.deepapp.it/UsersLogin.aspx>

1. Create an account with an email address and a password
2. Then, log in with the following **PIN: MED2024** and register for the congress

For further information: <https://www.3psolution.it/>

email: ciufo@3psolution.it

mobile: 338 5089489

To obtain CME credits, it is necessary to:

1. Attend at least 90% of the accredited CME sessions (attendance check: required signature at the beginning and at the end of the scientific program)
2. Complete the online learning questionnaire and answer at least 75% of the questions correctly. The evaluation will be available in the CME section of the DEEP platform after verification of actual attendance at at least 90% of the scientific sessions. It will be possible to fill in the questionnaire within three days (72 hours) after the event. It will be possible to fill in the questionnaire only once (non-repeatable)
3. Fill in the event evaluation questionnaire.

The certificate of participation and the certificate with CME credits can be downloaded directly from the corresponding section of the platform once you have completed the above.


Official congress language: Italian

Sponsored by an unrestricted grant from:

SILVER SPONSOR



SPONSOR



CME PROVIDER AND ORGANIZING SECRETARIAT



Sede legale:
via Borgogna, 2 - 20122 Milano
Sede operativa:
corso Europa, 13 - 20122 Milano
mail | info@3psolution.it



web | www.3psolution.it

RINNOVO ACCREDITAMENTO STANDARD notifica del 26 luglio 2019